Nyrada Inc (NYR)

NYR Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 9-day 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 6m 1yr 5yr 10yr

NYR's Principal Activity is the development of therapeutic treatments for cardiovascular, neurological and inflammatory/autoimmune diseases, testing and optimization of novel drug candidates while building on the Company's patent portfolio.

Announcements

Company Overview

Dividend History

Directors & Management

Name	Title	Since	Bio
Dr Ian Edward Dixon	Founder,Non-Executive Director	Sep 2020	Dr Ian Edward Dixon Founder,Non-Executive Director Dr Dixon has more than 20 years' experience in the Australian sector. Ian is a co-inventor of the technology behind its Cholesterol Lowering Program, giving him experience in the development of PCSK9 inhibitors. Dr Dixon is also Chairman and founder of Altnia Group, a privately held Australian biotechnology incubator and life sciences R&D company. Currently Founder and Managing Director of exosome medicine company, Exopharm (ASX: EX1), Dr Dixon also serves as a part-time executive director of Medigard Ltd (ASX: MGZ). In addition, Dr Dixon co-founded Cynata Inc. - now a subsidiary of Australian listed biotechnology company, Cynata Therapeutics Ltd (ASX: CYP). Until recently he was a non-executive director of Noxopharm Ltd (ASX: NOX). Dr Dixon was a director of Cell Therapies Pty Ltd.
Mr Christopher Cox	Non-Executive Director	Nov 2019	Mr Christopher Cox Non-Executive Director Mr Cox has been a partner at Cadwalader, Wickersham & Taft LLP in New York since January 2012. Previously the Chairman of Cadwalader's Department and a Member of its Management Committee, he advises clients on a of corporate and financial matters, including mergers and acquisitions and restructurings, spin-offs, joint ventures, IP monetizations and other financing transactions. From February 2016 to March 2019, he was seconded to The Medicines Company, a biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was in charge for business development and strategy. Prior to January 2012, he was a partner at Cahill Gordon & Reindel LLP in New York. He also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a investment holding company with interests in biotechnology, network security and entertainment. He was also a Member of the Missouri Law Review.
Mr John Alexander Moore	Non-Executive Chairman,Non-Executive Director	Jun 2019	Mr John Alexander Moore Non-Executive Chairman,Non-Executive Director Mr Moore currently serves as Chairman of Trialogics a clinical trial informatics business. He was CEO of Acorn Energy from 2006 to 2015. In 2002 he was a partner and CEO of Edson Moore Healthcare Ventures. He is a director of Scientific Industries, a producer of laboratory instruments for the life sciences industry.
Mr Ruediger Weseloh	Non-Executive Director	Jun 2019	Mr Ruediger Weseloh Non-Executive Director Mr Weseloh is a Director of Business Development at Merck KgaA, Darmstadt, Germany, where, in 14 years of doing BD, he has led it's transactions for the pharmaceutical division, doing deals across the drug development value chain in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before Merck KgaA, he spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Medicine in Goettingen. He also serves on the Supervisory Board of Cytotools AG, Freiburg, Germany.
Mr Marcus Frampton	Non-Executive Director	Jun 2019	Mr Marcus Frampton Non-Executive Director Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC). He manages the investment team at APFC and leads all investment decisions related to the APFC's investment portfolio within the guidelines set up by APFC's Board of Trustees. Prior, he held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005), to equity investing at PCG Capital Partners (2005-2010), and acted as an executive of a equity-backed portfolio company at LPL Financial (2010-2012). He is also a shareholder and sits on the board of directors of Scientific Industries, Inc., a manufacturer of laboratory equipment and the owner of intellectual property related to bioprocessing systems.
Mr Peter Ashley Marks	Non-Executive Director	Aug 2017	Mr Peter Ashley Marks Non-Executive Director Mr Marks has over 30 years experience in corporate advisory, investment banking.
Mr David Franks	Company Secretary	N/A
Mr James Bonnar	Chief Executive Officer	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
02/03/21	John Moore	Buy	+19,000	$0.35	$6,650	On-market trade
02/03/21	John Moore	Buy	+500	$0.204	$102	As advised by the company
23/02/21	Marcus Frampton	Buy	+25,000	$0.357	$8,925	On-market trade
18/01/21	Ian Dixon	Issued	1,800,000	$0.40	$720,000	Director remuneration
25/11/20	John Moore	Buy	+32,000	$0.206	$6,600	On-market trade
24/11/20	Marcus Frampton	Buy	+35,000	$0.21	$7,350	On-market trade
10/09/20	John Moore	Buy	+32,500	$0.21	$6,825	On-market trade
23/04/20	John Moore	Buy	+35,000	$0.168	$5,882	On-market trade

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
John Moore	02/03/2021	281,500	N/A	3,600,000	N/A
Marcus Frampton	23/02/2021	170,075	N/A	1,800,000	N/A
Ian Dixon	18/01/2021	N/A	9,921,725	1,800,000	N/A
Christopher Cox	30/06/2020	N/A	800,000	1,800,000	N/A
Ruediger Weseloh	30/06/2020	N/A	N/A	1,800,000	N/A
Peter Marks	30/06/2020	N/A	50,000	2,600,000	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Noxopharm Limited	33,373,245	30.51%
Altnia Holding Pty Ltd <I Dixon Family A/C>	9,921,725	9.07%
Goodridge Nominees Pty Ltd <The Goodridge Family A/C>	4,600,000	4.21%
Goodridge Foundation Pty Ltd <The Goodridge Foundation A/C>	3,450,000	3.15%
Colin Housely & Freda Housely <Cm Housley & Fv Housley Fam>	1,863,725	1.70%
Sunset Capital Management Pty Ltd <Sunset Superfund A/C>	1,500,000	1.37%
Kohen Enterprises Pty Ltd	1,335,000	1.22%
John W King Nominees Pty Ltd	1,242,483	1.14%
Goodridge Nominees Pty Ltd <The Goodridge Family A/C> i	1,212,416	1.11%
Goodridge Foundation Pty Ltd <Goodridge Foundation A/C>	1,212,416	1.11%
Rhlc Pty Limited <Rhlc S/F A/C>	1,000,000	0.91%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon <Mcmahon Super Fund A/C>	885,000	0.81%
Mr Graham Arthur Robinson	878,888	0.80%
Symphony Capital Holdings Llc	800,000	0.73%
Mr Anthony John Locantro	644,000	0.59%
Lawsam Pty Ltd	621,241	0.57%
Baywick Pty Ltd <Retail Discretionary A/C>	621,241	0.57%
Mr John Gardner	500,000	0.46%
Phytose Corporation Pty Limited <Boundaryone S/F A/C>	466,551	0.43%
Mr John Sellers	448,496	0.41%
Carda Pty Ltd <Carda Super Fund A/C>	405,000	0.37%
J P Morgan Nominees Australia Pty Limited	360,500	0.33%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.175	30 June

NYR Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.